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ABSTRACT
Objective To describe the quality assurance (QA) pro-
cesses and their impact on visualization of post-
menopausal ovaries in the ultrasound arm of a multicenter
screening trial for ovarian cancer.
Methods In the United Kingdom Collaborative Trial
of Ovarian Cancer Screening, 50 639 women aged
50–74 years were randomized to the ultrasound arm
and underwent annual transvaginal ultrasound (TVS)
examinations. QA processes were developed during the
course of the trial and included regular monitoring
of the visualization rate (VR) of the right ovary.
Non-subjective factors identified previously as impacting
on VR of the right ovary were included in a generalized
estimating equation model for binary outcomes to
enable comparison of observed vs adjusted VR between
individual sonographers who had undertaken> 1000
scans during the trial and comparison between centers.
Observed and adjusted VRs of sonographers and centers
were ranked according to the highest VR. Analysis of
annual VRs of sonographers and those of the included
centers was undertaken.
Results Between June 2001 and December 2010, 48 230
of 50 639 women attended one of 13 centers for a total
of 270 035 annual TVS scans. One or both ovaries were
seen in 228 145 (84.5%) TVS scans. The right ovary
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was seen on 196 426 (72.7%) of the scans. For the 78
sonographers included in the model, the median difference
between observed and adjusted VR was −0.7% (range,
−7.9 to 5.9%) and the median change in VR rank after
adjustment was 3 (range, 0–18). For the 13 centers, the
median difference between observed and adjusted VR was
−0.5% (range, −2.2 to 1%), with no change in ranking
after adjustment. The median adjusted VR was 73%
(interquartile range (IQR), 65–82%) for sonographers
and 74.7% (IQR, 67.1–79.0%) for centers. Despite the
increasing age of the women being scanned, there was a
steady decrease in the number of sonographers with VR
< 60% (21.4% in 2002 vs 2.0% in 2010) and an increase
in sonographers with VR > 80% (14.3% in 2002 vs
40.8% in 2010). The median VR of the centers increased
from 65.5% (range, 55.7–81.0%) in 2001 to 80.3%
(range, 74.5–90.9%) in 2010.
Conclusions A robust QA program can improve visu-
alization of postmenopausal ovaries and is an essential
component of ultrasound-based ovarian cancer screening
trials. While VR should be adjusted for non-subjective
factors that impact on ovarian visualization, subjective
factors are likely to be the largest contributors to dif-
ferences in VR. © 2015 The Authors. Ultrasound in
Obstetrics & Gynecology published by John Wiley &
Sons Ltd on behalf of the International Society of Ultra-
sound in Obstetrics and Gynecology.
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INTRODUCTION
The safe and effective delivery of a cancer-screening
program depends on the provision of a high-quality
service, continued development of the personnel delivering
and running the service and a systematic approach linking
all the activities involved in the identification of the
cancer1. To monitor and evaluate these processes, quality
assurance (QA) programs are essential. They are major
contributors to the success of the breast and cervical
screening programs in the UK. QA processes are often
developed during the course of screening trials to facilitate
future clinical implementation if appropriate. This is
especially relevant to screening tests with a significant
subjective element such as transvaginal ultrasound (TVS),
which is integral to screening strategies for ovarian
cancer2.
In the last decade, four major ovarian cancer screening
trials with different screening protocols have evaluated
the efficacy of TVS as a screening test, with variable
results3–6. The single-center Kentucky Ovarian Cancer
Ultrasound Screening study reported a possible survival
benefit3, whereas screening using a combination of TVS
and CA 125 did not result in a stage shift in the
Japanese Shizuoka Cohort study4 or demonstrate a
mortality benefit in the USA Prostate, Lung, Colorectal
and Ovarian (PLCO) screening trial5. The mortality
impact of screening in the United Kingdom Collaborative
Trial of Ovarian Cancer Screening (UKCTOCS)6, which
completed screening in 2011, is awaited.
One of the concerns regarding the use of ultrasound
in screening has been the considerable interobserver
variability reported in ovarian visualization in large
screening studies, and the fact that the accuracy of
interpretation depends on the operator’s experience2.
Here we describe the methods used to ensure delivery of
high-quality ultrasound scanning in a multicenter setting,
to define parameters for QA during TVS examination of
postmenopausal ovaries and to assess the impact of QA
processes over time on visualization rates (VR) of the
ovary for individual sonographers and regional centers,
after adjustment for non-subjective factors that can impact
on VR2.
METHODS
Participants, design and follow-up within
the UKCTOCS
Details regarding volunteers and design of the trial
have been described previously in greater detail6,7. In
brief, of the 202 638 women recruited to the trial,
50 639 were randomized to the ultrasound arm and
underwent annual TVS screening between October
2001 and December 2011. Transabdominal ultrasound
(TAS) was undertaken only when TVS was declined
by the participant. The examinations were performed
by sonographers at 13 participating regional centers.
All scan data were entered contemporaneously on a
central web-based trial management system. Women were
followed up for a diagnosis of cancer through a ‘flagging
study’ via the Health and Social Care Information Center
(formerly the UK Office of National Statistics) and
through postal questionnaire sent 31/2 years after the
women were randomized to the trial. This analysis was
restricted to all women in the ultrasound group who had
a scan by 31 December 2010. The UKCTOCS study was
approved by the UK North West Multicentre Research
Ethics Committees (North West MREC 00/8/34). It
is registered as an International Standard Randomized
Controlled Trial, number ISRCTN22488978.
Ultrasound protocol
The ultrasound protocol addressed all aspects of scanning
during the trial. It included the standard operating
procedure (SOP) on scanning the pelvis in postmenopausal
women, which provided detailed guidance on the correct
techniques to accurately examine the pelvis (starting with
the uterus in the sagittal and transverse sections, reducing
the depth and following the ovarian ligament out to
the pelvic sidewall) and to identify the ovary based on
its ultrasound appearance (small static hypoechoic area
between the iliac vessel and ovarian ligament, adjacent to
the iliac vessel anywhere along its length, and usually in
close proximity to the uterus). Measurement of three
ovarian diameters in two planes for the automated
calculation of ovarian volume by the trial management
system was detailed, as were suggestions for image
optimization (abdominal palpation to displace the bowel,
using the dual screen, manipulating the image to view
the ovary in the middle of the screen, increasing the
depth or using zoom to magnify the image of the ovary,
positioning focus correctly, using frequency to improve
resolution at required depth, slow frame rates and using
the scroll facility to obtain the best frame after freezing).
The classification and reporting of ovarian/adnexal lesions
were standardized. Algorithms for the management of the
findings are detailed elsewhere6.
If the sonographer, the trial center team or the center’s
lead consultant had concerns regarding an ultrasound
examination, they could request a review of the images by
a senior UKCTOCS investigator with ultrasound expertise
at the coordinating center.
Ultrasound machines
Dedicated centrally procured ultrasound machines with
service contracts were used across the regional centers.
At all centers, the Kretz SA9900 ultrasound machine
(Medison, Seoul, South Korea) was used between 2001
and 2007, followed by the Medison Accuvix ultrasound
machine from 2007 to 2011. At the beginning of the trial,
and when ultrasound machines were upgraded, centers
were visited to ensure uniform settings were used on all
machines. The ultrasound machines were calibrated and
maintained regularly under a centrally agreed UKCTOCS
service contract.
© 2015 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2016; 47: 228–235.
on behalf of the International Society of Ultrasound in Obstetrics and Gynecology.
230 Sharma et al.
Key components of the QA process
Ultrasound subcommittee
Implementation of the ultrasound arm and set up and
running of the QA processes were overseen initially
by the team at the coordinating center and the trial
investigators with ultrasound expertise. In 2006, a formal
ultrasound subcommittee was formed. Chaired by the
trial coordinator, the committee included senior trial
gynecologists with expertise in gynecological imaging,
radiologists experienced in abdominal and pelvic imaging,
a national lead sonographer (NLS) for the trial, senior
sonographers from regional centers and the coordinating
center team, who were involved in day-to-day monitoring
of the ultrasound protocol and QA process. The
subcommittee managed the training and set up an
accreditation process for sonographers, monitoring of
adherence to the ultrasound protocol, fail-safe monitoring
and further development of the QA processes. They also
had oversight of the logistics involved in implementation
of the ultrasound arm of the trial. The subcommittee met
three times a year with e-mail updates from the NLS on a
monthly basis.
National lead sonographer (NLS)
The NLS was a senior sonographer (superintendent level)
with extensive experience in gynecological scanning and
management of sonographers. She was appointed to
the coordinating center team to oversee the day-to-day
delivery of ultrasound across regional centers and take
on QA management and execution of the ultrasound
subcommittee’s recommendations. Central to this were
assessing and addressing the training needs of each
sonographer, developing a system for their accreditation
and re-accreditation, running weekly fail-safe checks on
scan reports to monitor discrepancies or errors and
implementing QA monitoring. In addition, the NLS
worked with the regional centers to manage the logistics
of delivering an average of 3000 scans per center per
year following the end of recruitment. In her absence, the
clinical research fellow ran the fail-safe checks and QA
monitoring.
Personnel scanning in trial
Type 1 sonographers (certified sonographers, trained
midwives or doctors in the National Health Service (NHS)
trained in gynecological scanning) performed TVS as a
first line-test (level 1) in the ultrasound arm6. If the
results of the level 1 scan were normal, the women were
returned to annual screening and scanned the following
year by a type 1 sonographer. However, on detection of an
abnormality on the level 1 scan, a repeat scan (level 2) was
arranged6. These were performed by type 2 sonographers
(senior sonographers, usually at superintendent level,
experienced gynecologists or radiologists) with expertise
in gynecological scanning6.
Induction of sonographers
Each sonographer commencing scanning in the trial
was required to submit their curriculum vitae giving
details of their qualifications and scanning experience.
They received a current copy of the scanning protocol.
On-site training was provided to familiarize each with
the protocol and recommended methods of scanning
before scanning independently on the trial. The NLS,
designated senior trial gynecologists or radiologists
with ultrasound expertise or, occasionally, a delegated
experienced local sonographer, supervised the new
sonographer for a minimum of two scanning sessions,
assessed competency and then authorized the sonographer
to scan independently in the trial. A practical assessment
was arranged 3 months after the sonographers joined the
trial and this was later incorporated into the accreditation
process.
Ongoing training of sonographers
Central training days, often spanning weekends, were
organized twice a year for sonographers, nurses and
other members of the regional center teams. This
training included talks on recommended and standardized
scanning techniques, definitions of key terms, quality
checks and the ultrasound protocol. A mandatory
component was a 2-h case-based discussion session that
included both screen-detected and screen-missed (interval)
cancers with an emphasis on the availability of a second
opinion when faced with equivocal scan findings. It
was obligatory for all sonographers to attend at least
one study day per year. In addition, all centers were
visited at the start, and on a regular basis during the
course of the trial, by senior investigators with ultrasound
expertise, accompanied by the clinical fellow or NLS.
These visits included formal practical training sessions,
talks to reinforce key messages and one-to-one scanning
and assessment, especially of those identified on QA
monitoring to have ovarian VRs below 60%.
The coordinating center also circulated newsletters to
the sonographers and regional center nurses, communi-
cating updates and news from the regional centers.
Accreditation for individual sonographers was initiated
in 2008 and comprised completion of a questionnaire
to demonstrate understanding and knowledge of the
UKCTOCS protocol, assessment of VR by review of
scan data over a 3-month period, practical assessment
by the NLS, which included scanning of a minimum of
five volunteers, and submission of nine sets of images for
central review by the NLS and a subcommittee member
with expertise in pelvic scanning.
Ultrasound data collection and data entry
Scan data regarding visualization of the ovaries, reasons
for non-visualization of the ovaries, morphological
findings of the ovary, details of any abnormality seen,
endometrial thickness measurements, presence of free
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fluid in the pouch of Douglas and any other abnormalities
were recorded on a standard data form. In addition,
the overall pictorial impression of abnormal morphology
was collected initially using the Kentucky pictorial
representation of morphology index and subsequently,
from 2004, using the International Ovarian Tumor
Analysis Group pictorial classification8,9.
The sonographer or a member of the local team
collated and entered the information online contempo-
raneously on a dedicated ultrasound reporting section
of the web-based trial management system7. The coor-
dinating center provided on-site training and written
instructions on how to enter the data and conducted
regular on-site visits to monitor and audit data entry
on the trial management system to ensure accuracy
of entries.
Following entry of scan findings on the trial manage-
ment system, there was central automated classification
of scan results based on visualization, morphology and
size of simple cysts and recommended management6.
Results letters were sent to the volunteers directly from
the coordinating center, as were appointment letters for
their next scan. There was daily regional monitoring of
the automated management decisions and weekly cen-
tral monitoring of any data discrepancies, with editing
of incorrect entries and update of management deci-
sions if required. All errors in data entry were fed back
immediately and discussed with the regional center team
coordinators and individual sonographers.
Fail-safe monitoring
Several monitoring mechanisms were implemented. These
were overseen by the clinical fellow or the NLS, who ran
a series of data queries and read all free text entered
on the ultrasound report to detect: (1) discrepancies
between the notes and the mandatory classification
fields; (2) missing ovarian dimensions when ovaries
were visualized; (3) missing descriptions of complex
masses; (4) apparent errors in measurement; and (5)
incidental findings. All queries were investigated by
contacting the regional center team, who reviewed the
written scan report and the images as appropriate. The
NLS or fellow then corrected data entries on the trial
management system. The regional center nurses were
also alerted to ensure that all women with significant
incidental findings had been referred appropriately to their
general practitioner or the hospital team as per locally
agreed guidelines.
Archiving and review of images
Gray-scale images of ultrasound scans performed during
the trial were archived. The protocol defined the views
to be stored. For a normal scan, transverse and sagittal
views of each normal ovary with measurements and a
section through the uterus, including the endometrial
thickness measurement, were stored. For an abnormal
scan, images with measurements of any mass in two
perpendicular planes were stored. If Doppler was used,
the frames demonstrating the waveforms and calculations
and the images of any incidental abnormalities were
stored. Images were archived initially on the ultrasound
machines at the centers and were then transferred
weekly or biweekly (depending on volumes) on a
magneto-optical disc to the coordinating center for
central archiving. Regular reviews of images of interval
cancers were conducted, with feedback given to individual
sonographers and discussion at the annual ultrasound
meetings. In addition, the NLS or senior members of the
ultrasound subcommittee reviewed all images for which
concern was raised on fail-safe monitoring of the scan
reports.
Quality assurance monitoring
Since visualization of the ovary is essential to identify
any morphological abnormality of the ovary, it was
considered the most important metric for QA in the
trial. The sonographers were required to indicate whether
each ovary was seen; was not seen but a good view of the
pelvis was obtained; was not seen with a poor view of the
pelvis; or was not seen owing to previous oophorectomy.
It was decided that ‘visualization of the ovary’ would be
the primary QA measure, as this could be verified by
review of archived images when required. As we did not
observe a substantial difference in VR between the right
and left ovary on TVS, monitoring was based on the VR of
the right ovary10. Unadjusted VRs of the right ovary were
calculated on a 6-month basis for individual sonographers
undertaking more than 1000 scans during the trial period
and for individual regional centers. We set a standard
for observed unadjusted VR of the right ovary of 60%,
based on data derived from the first 2 years of scanning in
UKCTOCS and the report of VRs of one or both ovaries
(data for individual ovaries were not available) from the
Kentucky screening study11. Other metrics used for QA
monitoring included median volume of normal ovary and
missing or incorrect data in key fields, such as ovarian
measurements. Reports incorporating coded individual
and center data were circulated to all involved in the trial.
Center leads were informed of their regional codes so that
they could discuss the report in detail with their team of
sonographers. In addition, the NLS contacted individual
outliers for targeted training and worked with them to
improve their VR.
Statistical analysis
Descriptive statistics were used to describe baseline
characteristics of the women according to which
sonographer performed the scan and to the center at
which they were examined.
The VR of the right ovary was adjusted for the strongly
significant (P< 0.01) non-subjective factors identified in
a previous study (age, hysterectomy, oophorectomy with
intact uterus, age at menopause, tubal ligation, body mass
index)10. For individual women, the ability to visualize the
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ovary is likely to be correlated across annual scans. The
VR was therefore modeled, taking into account clustering
of outcomes. To provide population-averaged rather than
individual-level effects of covariates on visualization, we
fitted a generalized estimating equation model for binary
outcomes, with a logit link function and an ‘exchangeable’
correlation structure. Such a model is similar to a standard
logistic regression model but with a specified intraperson
correlation structure. Sonographers who had performed
more than 1000 scans in total between 2001 and 2010
were included as separate fixed effects in the model.
These sonographers were compared with a reference
group consisting of those who had performed ≤ 1000
scans. A separate model that included the individual
center effects (but with no sonographers) was also fitted.
Age at first scan indicated the actual age effect, whereas
scan year reflected the trend in ultrasound performance.
Odds ratios for individual sonographers and centers
reflected performance relative to the reference group.
Comparison of model-based adjusted VR with observed
VR for individual sonographers and centers helped to
indicate how the differences in the non-subjective factors
impacted on the VR of sonographers and centers. It
was an indicator of the need for adjustment of VR
in this setting. Rankings for the observed and adjusted
VRs (1 = highest VR) reflected the impact of these
adjustments.
Annual trends of observed VR of the right ovary
between 2001 and 2010 were plotted for individual
sonographers and regional centers. The VRs calculated
for each center included all scans performed at the center
during that calendar year. Annual observed VR of the
right ovary for individual sonographers was limited to
sonographers who had undertaken> 1000 level-1 TVS
examinations overall and > 100 during that calendar
year.
RESULTS
Between 11 June 2001 (date of commencement of
scanning in the trial) and 31 December 2010, across
13 regional centers, 48 230 of the 50 639 women in the
ultrasound screening arm attended at least one screening
examination and underwent a total of 293 732 annual
scans. Of these, 23 697 were TAS examinations and
were excluded from the analysis. The remaining 270 035
scans comprised 267 036 TVS examinations and 2999
in which both TVS and TAS were performed. The right
ovary was seen in 196 426 (72.7%) scans, and was not
visualized but there was a good view of the pelvis in 62 683
(23.2%) and a poor view of the pelvis in 6429 (2.4%);
a previous unilateral oophorectomy was noted in 4493
(1.7%). Four scans were unrecorded. The VR of the left
ovary was 69.7% (188 347/270 035) and the VR of one or
both ovaries was 84.5% (228 145/270 035). The 270 035
annual scans between 2001 and 2010 included in the trial
were performed by 294 sonographers. However, 222 666
(82.5%) were undertaken by 78 sonographers who
had performed> 1000 scans at a center. The remaining
scans (47 369) formed the reference group in the model
comparing individual sonographers.
We reported previously that age at scan, age at
menopause, being overweight, previous hysterectomy,
previous sterilization and unilateral oophorectomy with
intact uterus were significant predictors of VR10. These
were used in the longitudinal analysis along with the scan
year to reflect the overall trend in scanning performance
(Table S1). The mean baseline characteristics of the
women scanned by the 78 individual sonographers
with> 1000 scans showed more variability than was
found in the mean baseline characteristics of the women
scanned in the different centers but with no evidence of
any large systematic differences. For example, the mean
age ranged between 59.5 and 63.3 years and hysterectomy
rate ranged between 14.2% and 22.0% (Table S2).
The median adjusted VR for sonographers was 73%
(interquartile range (IQR), 65–82%). The observed VR
was outside the 95% CI of the adjusted VR for 38/78
(48.7%) sonographers included in the model. However
the median difference between observed and adjusted VRs
was only −0.7% (range, −7.9 to 5.9%). Adjustment of
VR changed the attainment of the trial standard VR of
60% in only 4/78 (5.1%) sonographers, increasing the
VR to ≥ 60% in two and decreasing the VR to< 60% in
two. However, the impact of adjustment on VR ranking
was greater, with a median change in rank of 3 (range,
0–18).
The baseline characteristics of women scanned at the
13 centers (Table S3) were similar, except for Center
G, which had the lowest hysterectomy rate (13.6%
vs overall average of 18.1%; range, 13.6–22.0%), the
lowest proportion of overweight or obese women, the
second lowest rate of tubal ligation and the highest rate of
infertility treatment. The median adjusted VR for the 13
centers was 74.7% (IQR, 67.1–79%), all centers having
an adjusted VR above the minimum standard of 60%.
The median difference between observed and adjusted
VR for the 13 regional centers was −0.5% (range,
−2.2 to 1%), with no change in ranking for any center
(Table S4).
Given the small differences between the observed and
adjusted VRs in our trial, the former was used to
determine trends over time. The annual observed VR
of individual sonographers who had performed more
than 1000 trial scans and of the 13 centers are detailed
in Table 1 and Figure 1, respectively. The number of
sonographers with VR<60% (21.4% in 2002 vs 2.0%
in 2010) decreased and those with VR> 80% (14.3% in
2002 vs 40.8% in 2010) increased over time, a trend that
was more pronounced after 2006. This is reflected in the
steady increase in the annual observed VR of ovaries at
individual centers (Figure 1). The median center-observed
VR increased from 65.5% (range, 55.7–81.0%) in 2001
to 80.3% (range, 74.5–90.9%) in 2010. The median
center-observed VR in 2003, after all 13 participating
centers became active, was 66.8%. In 2008 all centers
had a VR of > 60%, seven of the 13 centers achieving
overall VRs of > 80%.
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Table 1 Annual observed ovarian visualization rates (VR) of right ovary for 78 sonographers who had each performed >1000 scans during
United Kingdom Collaborative Trial of Ovarian Cancer Screening
Year
Parameter 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Number of sonographers 1 14 33 54 57 64 65 64 54 49
Observed VR
< 50% — 3 (21.4) 6 (18.2) 9 (16.7) 8 (14.0) 9 (14.1) 5 (7.7) 1 (1.6) — —
50–60% — — — 5 (9.3) 10 (17.5) 8 (12.5) 3 (4.6) 5 (7.8) 4 (7.4) 1 (2.0)
60–80% 1 (100) 9 (64.3) 15 (45.5) 20 (37.0) 20 (35.1) 30 (46.9) 34 (52.3) 35 (54.7) 30 (55.6) 28 (57.1)
> 80% — 2 (14.3) 12 (36.4) 20 (37.0) 19 (33.3) 17 (26.6) 23 (35.4) 23 (35.9) 20 (37.0) 20 (40.8)























Figure 1 Annual visualization rates (VR) of the right ovary by
transvaginal ultrasound in 48 230 postmenopausal women
attending one of 13 regional centers from 2001–2010. Thick lines
indicate adjusted VR ( ) and median observed VR ( ).
Thin lines represent each of the 13 centers.
DISCUSSION
Our report is the first detailed description of QA processes
required for delivering TVS in large multicenter ovarian
cancer screening trials or programs and for evaluating
their impact on ovarian visualization. Our results show
that the QA processes developed, together with regular
monitoring, can lead to a high VR of postmenopausal
ovaries and ensure continual improvement in VR over
time. The VR showed a steady increase over the years,
with the majority of sonographers and all centers
achieving a VR of individual ovaries of > 60%. The
differences in VR partly reflect the differing scanning
abilities of individual sonographers. It is important to
highlight that ovarian VR is not a perfect metric, as it
underestimates pelvic visualization by not defining scans
as ‘visualized’ when ovaries are not seen but there is a
good view of the pelvic sidewall or when unilateral ovaries
are not seen owing to previous oophorectomy.
A key finding was that differences between observed
and adjusted VRs were small. Adjustment had the great-
est impact on individual sonographer ranking. This
probably results from differences in non-subjective fac-
tors being small between centers and being more pro-
nounced between individual sonographers. The persistent
difference in adjusted VR confirms that subjective factors,
i.e. individual skill, attention to detail and experience, are
major contributors, in keeping with previous reports that
subjective assessment of the gray-scale image has the high-
est accuracy12–14. It is likely that QA processes coupled
with central monitoring and targeted training impacted
on both non-subjective and subjective factors.
Ovarian visualization is key to identifying morphologi-
cal abnormalities that may be indicative of ovarian cancer.
Our VR of one or both ovaries was 84.5% in an analy-
sis of 270 035 TVS examinations. This was higher than
that reported in the PLCO trial5 which, like UKCTOCS,
was a multicenter trial in which postmenopausal women
underwent annual screening. Bodelon et al.15 reported
an ovarian VR (one or both ovaries visualized) of 53%
in their most recent analysis of 102 787 scans involving
29 321 women. Both subjective and non-subjective fac-
tors could have contributed to these differences. The rates
probably reflect differences in delivery of ultrasound and
may have contributed to differences in the stage (UKC-
TOCS Stages I/II: 48% vs PLCO Stages I/II: 22%) of
screen-detected cancers on prevalence screening in the
two trials5,6. Our VR was similar to that reported in
the Kentucky ovarian cancer screening study (84%), in
which 25 327 women underwent a total of 120 569 scans
during an 18-year period3. This study, unlike UKCTOCS,
was limited to a single center with scanning performed
by a small group of experienced personnel. Their cohort
included a proportion of younger premenopausal women,
in whom the presence of follicles makes ovaries eas-
ier to visualize. Neither study reported on the VR of
individual ovaries as we have done for QA monitoring
in UKCTOCS. Higher ovarian VR (right, 84.1%; left,
82.4%) was reported in a retrospective 5-year audit of
6649 postmenopausal women who underwent TVS as
part of clinical evaluation in a gynecological ultrasound
department16. The higher rates most probably reflect the
scanning expertise available at tertiary centers and also
the higher incidence of adnexal pathology (which may
make visualization easier) in a clinical, compared to an
asymptomatic, cohort attending screening.
In UKCTOCS, sonographers performed the annual
level 1 scans. This reflects the practice in the UK NHS,
in which sonographers perform the vast majority of
pelvic ultrasound scans. It would be difficult to find
the resources required for expert gynecologists to deliver
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primary screening in a national screening program or
large multicenter trial involving > 50 000 scans yearly.
However operator experience is crucial for accurate
interpretation2 and patients with adnexal masses undergo
fewer operations and a greater number of minimally
invasive procedures, and experience shorter hospital stays,
when scanned by experienced gynecologists than do those
scanned by sonographers17. Hence, level 2 scans following
the detection of an abnormality were performed by a
senior sonographer or expert gynecologist or radiologist.
Individual sonographer and center VRs increased over
time despite the increasing age of the participants. This
could partly be explained by the increasing experience of
the sonographers, some of whom continued to participate
in the trial for many years. However, the ongoing QA
processes with their focus on sonographer training and
support, regular monitoring with feedback and targeted
training are likely to have contributed significantly to
this increase. The SOP for examining the pelvis in
postmenopausal women was introduced to sonographers
at induction. It reaffirmed the principles of TVS
scanning and emphasized a systematic approach to pelvic
examination, identification of ovaries and optimization
of images. The NLS as a quality-control manager was
key to the interaction with sonographers. In addition, the
introduction of accreditation contributed to improving
ultrasound quality. The British Society for Gynaecological
Imaging has adopted the UKCTOCS scanning SOP
as guidance for good practice and incorporated the
accreditation scheme with modifications into the Society’s
continuing professional development program.
This report demonstrates the benefits of a formal QA
process and outlines the procedures to be implemented
for multicenter ultrasound screening. By introducing
training days and familiarizing sonographers with the
scanning protocol and SOPs, uniformity in scanning
postmenopausal ovaries and interpreting gray-scale
ultrasound images was maintained. The leadership
provided by the subcommittee and the attention to detail
and sonographer support and training provided by the
NLS were key to the sustained improvement in VR. The
process of accreditation was of immediate use to those
who wished to maintain standards in pelvic scanning.
Limitations include the fact that QA processes were set
up in the course of the trial and the NLS was appointed
only midway through the trial. At the start of the trial
the standard for VR of the right ovary was set at 60%,
but the improvement over time suggests that this could
have been set higher. In addition, independent review of
the archived images to assess visualization of the ovaries
is yet to be completed.
In conclusion, if there are robust centrally implemented
and monitored QA processes, ovarian VR as a perfor-
mance indicator of the quality of ultrasound screening
will improve with time, despite adverse factors such as
aging. While VR should be adjusted for non-subjective
factors that impact on ovarian visualization, it is likely
that subjective factors will be the largest contributors to
VR differences.
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SUPPORTING INFORMATION ON THE INTERNET
The following supporting information may be found in the online version of this article:
Table S1 Generalized estimating equation model for binary outcomes for comparison of observed and
adjusted visualization rates (VR) of the right ovary on ultrasound for 78 individual sonographers who had
performed>1000 scans during the United Kingdom Collaborative Trial of Ovarian Cancer Screening,
including non-subjective factors identified previously as impacting on VR
Table S2 Mean baseline characteristics of 48 230 postmenopausal women scanned by 78 individual
sonographers with> 1000 scans performed during the United Kingdom Collaborative Trial of Ovarian
Cancer Screening
Table S3 Mean baseline characteristics of 48 230 postmenopausal women scanned at one of 13 regional
centers during the United Kingdom Collaborative Trial of Ovarian Cancer Screening
Table S4 Generalized estimating equation model for binary outcomes for comparison of observed and
adjusted visualization rates (VR) of the right ovary on ultrasound at 13 regional centers participating in
United Kingdom Collaborative Trial of Ovarian Cancer Screening, including non-subjective factors identified
previously as impacting on VR
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